Journal
CANCER CELL
Volume 13, Issue 6, Pages 529-541Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2008.04.019
Keywords
-
Categories
Funding
- NICHD NIH HHS [1R01 HD055300, R01 HD055300-01, R01 HD055300] Funding Source: Medline
- NIMH NIH HHS [K08 MH01750, K08 MH001750-05] Funding Source: Medline
Ask authors/readers for more resources
Genetic and epigenetic defects in Wnt/beta-catenin signaling play important roles in colorectal cancer progression. Here we identify DACT3, a member of the DACT (Dpr/Frodo) gene family, as a negative regulator of Wnt/beta-catenin signaling that is transcriptionally repressed in colorectal cancer. Unlike other Wnt signaling inhibitors that are silenced by DNA methylation, DACT3 repression is associated with bivalent histone modifications. Remarkably, DACT3 expression can be robustly derepressed by a pharmacological combination that simultaneously targets both histone methylation and deacetylation, leading to strong inhibition of Dishevelled (Dvl)-mediated Wnt/beta-catenin signaling and massive apoptosis of colorectal cancer cells. Our study identifies DACT3 as an important regulator of Wnt/beta-catenin signaling in colorectal cancer and suggests a potential strategy for therapeutic control of Wnt/beta-catenin signaling in colorectal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available